Interaction of retinoic acid and vitamin D3 analogs on HL-60 myeloid leukemic cells
Abstract
Retinoic acid (RA) is an interesting agent which has been shown to induce differentiation and complete remission in patients with acute promyelocytic leukemia. 1,25-(OH)2-delta 16-23-yne-cholecalciferol (16-23-D3) and 1,25-(OH)2-23-yne-cholecalciferol (23-D3) are vitamin D3 analogs capable of inducing differentiation of myeloid leukemic cells with little effect on either calcium absorption or mobilization.
Using HL-60 myeloid leukemic cells as in vitro model for human acute myeloid leukemia we observed an additive to synergistic interaction between RA and 16-23-D3 or 23-D3 with respect to the inhibition of cell growth and DNA synthesis, the induction of differentiation and the loss of cell clonogenicity.
In addition, we observed that RA and 16-23-D3 interact additively with respect to the reduction of c-myc mRNA expression.
These results suggest that Ra used in combination with 16-23-D3 or 23-D3 may be an interesting chemotherapeutic regimen to evaluate in patients with acute myeloid leukemia.
See also:
-Official Web Site: The Di Bella Method;
- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;
- The Di Bella Method (A Fixed Part - Dihydrotachysterol, Alfacalcidol, synthetic Vitamin D3);
- Vitamin D (analogues and/or derivatives) and cancer - In vitro, review and in vivo publications;
- The Di Bella Method (A Fixed Part - Calcium, 2 grams per day, orally);
- Large B-cells Non-Hodgkin's Lymphoma, Stage IV-AE: a Case Report;